Finanças

Discussões Sinais técnicos Sazonais

EBIT de CITI PHARMA LIMITED.

Dados anuais

2020

2021

2022

2023

2024

TTM

‪0,00‬

‪‪350,00 M‬‬

‪‪700,00 M‬‬

‪‪1,05 B‬‬

‪‪1,40 B‬‬

Período

Valor

Variação

Variação %

TTM

‪‪1,28 B‬‬

+‪‪187,79 M‬‬

+‪17,15‬%

2024

‪‪1,10 B‬‬

+‪‪3,09 M‬‬

+‪0,28‬%

2023

‪‪1,09 B‬‬

+‪‪184,33 M‬‬

+‪20,31‬%

2022

‪‪907,62 M‬‬

+‪‪371,92 M‬‬

+‪69,43‬%

2021

‪‪535,70 M‬‬

+‪‪296,71 M‬‬

+‪124,16‬%

2020

‪‪238,99 M‬‬

+‪‪111,03 M‬‬

+‪86,77‬%

Dados trimestrais

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

‪0,00‬

‪‪150,00 M‬‬

‪‪300,00 M‬‬

‪‪450,00 M‬‬

‪‪600,00 M‬‬

Período

Valor

Variação

Variação %

Q2 '25

‪‪437,75 M‬‬

+‪‪96,34 M‬‬

+‪28,22‬%

Q1 '25

‪‪341,42 M‬‬

+‪‪223,68 M‬‬

+‪189,99‬%

Q4 '24

‪‪117,73 M‬‬

‪‪−268,19 M‬‬

‪−69,49‬%

Q3 '24

‪‪385,93 M‬‬

‪‪−156,48 M‬‬

‪−28,85‬%

Q2 '24

‪‪542,41 M‬‬

+‪‪382,84 M‬‬

+‪239,92‬%

Q1 '24

‪‪159,57 M‬‬

+‪‪23,80 M‬‬

+‪17,53‬%

Q4 '23

‪‪135,77 M‬‬

‪‪−152,58 M‬‬

‪−52,92‬%

Q3 '23

‪‪288,35 M‬‬

‪‪−171,99 M‬‬

‪−37,36‬%

Q2 '23

Q1 '23

Q4 '22

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21